BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.

Press Releases Biohaven Pharmaceutical Holding Company Ltd.

Equities

BHVN

VGG111961055

Delayed Nyse Other stock markets 20:46:06 02/05/2024 BST			5-day change	1st Jan Change
39.91 ^USD	-0.67%		+3.77%	-73.69%

04-25	Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing	MT
04-23	Biohaven Shares Rise After Closing of Public Offering, Disclosure of Stock Purchase by CEO	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares	04-23	AQ
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares	04-19	AQ
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology Annual Meeting and Provides Other Business Updates	04-15	AQ
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments	03-01	AQ
Biohaven Highlights Progress across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference	01-09	AQ
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference	01-03	AQ
Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting	12-04	AQ
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments	11-15	AQ
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek	17/10/23	AQ
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares	06/10/23	AQ
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES	03/10/23	AQ
Biohaven Announces Positive Data from its Exploratory Electroencephalogram Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies	06/09/23	AQ
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments	01/08/23	AQ
Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy	01/08/23	AQ
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates	28/07/23	AQ
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day	01/06/23	AQ
Biohaven to Present R&D Day at Yale School of Management	26/05/23	AQ
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments	15/05/23	AQ
BIOHAVEN LTD. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)	04/05/23	AQ
BIOHAVEN LTD. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	24/03/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Biohaven Pharmaceutical Holding Company Ltd.

Equities

BHVN

VGG111961055

Press Releases

Filters